ARA-290 10mg
Cibinetide · EPO-derived innate repair receptor agonist
≥99.0%
Third-Party
COA
Complete your research kit
Also searched as: Cibinetide, ARA290
Third-Party Tested
HPLC & mass spec verified purity
Batch Specific COA
Certificate with every batch
Discreet Packaging
Plain, unbranded, tamper-evident
Same-Day Dispatch
Before 2PM AEST, Australia-wide
ARA-290 is a synthetic peptide developed from a specific region of erythropoietin (EPO) and is primarily investigated for its activity in cellular protection, inflammatory signalling and tissue-response research. Unlike EPO itself, ARA-290 is designed to investigate tissue-protective signalling without the same erythropoietic activity associated with red blood cell production. ARA-290 peptide research material is intended strictly for controlled laboratory and scientific investigation.
What Is ARA-290?
ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from the three-dimensional structure of erythropoietin. It was developed to reproduce selected tissue-protective properties associated with EPO signalling while minimising stimulation of erythropoiesis.
Research has focused particularly on its interaction with the innate repair receptor (IRR), commonly described as a heteromeric receptor involving the erythropoietin receptor (EPOR) and beta-common receptor (βcR/CD131).
This receptor pathway is of scientific interest because experimental models have associated it with cellular responses to inflammation, injury and metabolic stress.
Key Research Areas
ARA-290 research has examined several interconnected biological processes, including:
Preclinical and experimental findings should not be interpreted as evidence of established therapeutic benefit in humans.
Why Researchers Study ARA-290
One feature that distinguishes ARA-290 peptide research is its separation from the classical erythropoietic effects of EPO.
Researchers have investigated whether selective activation of tissue-protective receptor pathways can provide a useful experimental model for studying cellular repair and inflammatory signalling without strongly stimulating pathways responsible for red blood cell formation.
ARA-290 has consequently attracted research interest in models involving inflammatory responses, nerve function and cellular stress. Some clinical research has also examined cibinetide in specific disease settings, although such investigation does not establish ARA-290 research material as an approved treatment.
Key Research Areas at a Glance
ARA-290 in Australia
Researchers looking for ARA-290 online in Australia should evaluate suppliers based on transparent product specifications, analytical documentation and batch traceability.
Before ordering, confirm the current ARA-290 price, vial specification, stock status, testing information and Australian shipping arrangements. Batch-specific analytical documentation can also help laboratories verify that the material received corresponds with the stated research specification.
Specifications
Certificate of Analysis
Quality, Purity and Batch Testing
Analytical verification is important when evaluating ARA-290 purity and identity. Product documentation should clearly identify the nominal vial quantity and the analytical methods used for the specific batch.
Where available, researchers should consult the ARA-290 CoA for batch-specific information rather than relying solely on general product specifications.
Analytical purity should not be interpreted as evidence of clinical safety, suitability for human use or therapeutic effectiveness.
Storage & Handling
Storage and Laboratory Handling
- Lyophilised Storage: Follow the storage conditions stated on the product label and corresponding batch documentation.
- After Reconstitution: Where validated post-reconstitution stability information is not supplied, researchers should follow their established laboratory protocol and batch documentation.
Avoid assigning unsupported stability periods, solvents or reconstitution conditions.
Reconstitution calculator: ARA-290 10mg
Work out concentration and the volume to draw for each aliquot before you add diluent.
- Concentration
- –
- Volume per aliquot
- –
- On a 1 mL (U-100) syringe
- –
- Aliquots per vial
- –
A laboratory arithmetic aid only. Verify every calculation independently. Not dosing guidance; research use only.
ARA-290 10mg: Frequently Asked Questions
ARA-290 is an 11-amino-acid synthetic peptide derived from the structure of erythropoietin and studied primarily in tissue-protective and inflammatory signalling research.
It has been investigated for signalling through the innate repair receptor involving EPOR and CD131.
No. ARA-290 is derived from EPO but was designed to investigate selected tissue-protective signalling without EPO's conventional erythropoietic activity.
Research has examined inflammation, cellular stress, tissue injury responses and peripheral nerve-related mechanisms.
Researchers should refer to the specific product specification and batch analytical documentation for verified purity and testing information.
Availability depends on the supplier and batch. Where provided, the CoA should be checked for product-specific analytical results.
Follow the verified storage requirements supplied with the product and its batch documentation.
ARA-290 may be available through Australian research-peptide suppliers. Check current stock, price, testing documentation and domestic shipping before ordering.
No. This product is supplied strictly for in-vitro laboratory research. It is not approved for human or veterinary use and must not be consumed or administered.
Orders placed before 2PM AEST on business days are dispatched the same day from Melbourne. Standard Post takes 3–7 business days and Express Post 1–3 business days, both tracked and discreet.
Reviews
There are no reviews yet.